Table 3.

Subgroup analysis specific to spinal chordomas

Variables	TERT Promoter Mutation		P-value
	No (n = 84)	Yes (n = 8)
Sex (n = 92)			0.43*
Male	58 (69.1)	4 (50.0)
Female	26 (30.9)	4 (50.0)
Age at time of surgery (y) (n = 92)	60.4 ± 13.9	54.6 ± 14.0	0.27†
Spinal Level (n = 92)			0.05*
Mobile	32 (38.1)	0 (0.0)
Fixed	52 (61.9)	8 (100.0)
Ethnicity (n = 80)			0.34*
Non-caucasian	13 (18.1)	0 (0.0)
Caucasian	59 (81.9)	8 (100.0)
Adjuvant Therapy Given (n = 90)			0.10*
No	56 (68.3)	8 (100.0)
Yes	26 (31.7)	0 (0.0)
Timing of Chemotherapy (n = 90)			1.00*
Preop	2 (2.4)	0 (0.0)
Postop	3 (3.7)	0 (0.0)
Both	1 (1.2)	0 (0.0)
Neither (no chemo)	76 (92.7)	8 (100.0)
Timing of Radiation Therapy (n = 90)			0.61*
Preop	5 (6.1)	0 (0.0)
Postop	16 (19.5)	0 (0.0)
Both	3 (3.7)	0 (0.0)
Neither (no radiation)	58 (70.7)	8 (100.0)
Tumor Grade (n = 92)			1.00*
Low (I)	67 (79.8)	7 (87.5)
High (II)	17 (20.2)	1 (12.5)
Enneking Appropriateness (n = 89)			1.00*
EA	53 (64.6)	5 (71.4)
EI	29 (35.4)	2 (28.6)
Local Recurrence at 10 Years Postoperative (n = 92)			1.00*
No	53 (63.1)	5 (62.5)
Yes	31 (36.9)	3 (37.5)
Survival at 10 Years Postoperative (n = 92)			0.10*
Alive	56 (66.7)	8 (100.0)
Dead	28 (33.3)	0 (0.0)

Data are presented as N (%) or mean ± standard deviation; EA: Enneking appropriate, EI: Enneking inappropriate.

*Fisher’s exact test,^†Student’s t-test